OBJECT: Cavernous hemangiomas (cavernomas) are benign vascular malformations that may cause seizures and/or hemorrhage when they develop in the brain. The incidence of cavernoma development after brain radiotherapy is unknown. The aim of this study was to assess the prevalence of cavernoma formation in patients who had previously received radiotherapy for brain tumors during childhood. METHODS: All patients were identified who were younger than 16 years of age and had undergone radiotherapy for brain tumors within a 16-year period (January 1, 1988-December 31, 2003). The patient data that were ascertained included age at diagnosis, sex, histopathology results, initial preoperative magnetic resonance (MR) imaging results, date of radiotherapy, and date of detection of cavernoma. Children who were followed up for less than 1 month after radiotherapy or who died during treatment were excluded, as were children with brainstem tumors. All patients had undergone diagnostic MR imaging before receiving radiotherapy, and no vascular malformations were revealed. Of the 379 patients identified, 297 satisfied the inclusion criteria. Ten patients (3.4%) developed cavernomas after radiation therapy. The ages of these patients ranged from 2 to 11 years at the time of radiotherapy (median 7 years), and the latency interval between radiotherapy and cavernoma development was 3 to 102 months (median 37 months). CONCLUSIONS: The prevalence of cavernomas in the present study was more than six times greater than the prevalence rate cited in the literature for this population. The authors conclude that there is an increased risk of developing an intracranial cavernoma after radiotherapy for brain tumors. The possibility of this complication arising should be mentioned when informed consent is sought before treatment using radiotherapy.
OBJECT: Cavernous hemangiomas (cavernomas) are benign vascular malformations that may cause seizures and/or hemorrhage when they develop in the brain. The incidence of cavernoma development after brain radiotherapy is unknown. The aim of this study was to assess the prevalence of cavernoma formation in patients who had previously received radiotherapy for brain tumors during childhood. METHODS: All patients were identified who were younger than 16 years of age and had undergone radiotherapy for brain tumors within a 16-year period (January 1, 1988-December 31, 2003). The patient data that were ascertained included age at diagnosis, sex, histopathology results, initial preoperative magnetic resonance (MR) imaging results, date of radiotherapy, and date of detection of cavernoma. Children who were followed up for less than 1 month after radiotherapy or who died during treatment were excluded, as were children with brainstem tumors. All patients had undergone diagnostic MR imaging before receiving radiotherapy, and no vascular malformations were revealed. Of the 379 patients identified, 297 satisfied the inclusion criteria. Ten patients (3.4%) developed cavernomas after radiation therapy. The ages of these patients ranged from 2 to 11 years at the time of radiotherapy (median 7 years), and the latency interval between radiotherapy and cavernoma development was 3 to 102 months (median 37 months). CONCLUSIONS: The prevalence of cavernomas in the present study was more than six times greater than the prevalence rate cited in the literature for this population. The authors conclude that there is an increased risk of developing an intracranial cavernoma after radiotherapy for brain tumors. The possibility of this complication arising should be mentioned when informed consent is sought before treatment using radiotherapy.
Authors: Cynthia J Campen; Sarah M Kranick; Scott E Kasner; Sudha K Kessler; Robert A Zimmerman; Robert Lustig; Peter C Phillips; Phillip B Storm; Sabrina E Smith; Rebecca Ichord; Michael J Fisher Journal: Stroke Date: 2012-09-11 Impact factor: 7.914